journal article·2021-10-22

Fe3O4 Nanoparticles and Paraffin Wax as Phase Change Materials Embedded in Polymer Matrixes for Temperature-Controlled Magnetic Hyperthermia

Moshe Cohen-Erner, Raz Khandadash, Raphael Hof, Ofer Shalev, Adam Antebi, Arnoldo Cyjon, Dian Kanakov, Abraham Nyska, Glenwood Goss, John Hilton, Dan Peer

ACS Applied Nano Materials· Volume 4· Issue 10
Publisher page

Abstract

Over the last 2 decades, magnetic hyperthermia (MH) has been recognized as a promising concept for efficient cancer treatment. Recently, it has been receiving increased attention because of its procedure simplicity, noninvasive nature, and effective solid tumor heating with minimal damage to healthy surrounding normal tissues. In this paper, we report about the development of theranostic superparamagnetic iron oxide nanoclusters, demonstrating efficient heating in hyperthermia and good response under a magnetic resonance imaging (MRI) scan. Multiple cores of 25 ± 2 nm superparamagnetic iron oxide (Fe3O4) nanoparticles and paraffin wax based on 24-hydrocarbon chains (tetracosane), used as a phase change material, were coencapsulated in an interior core of a self-assembled PEO–PPO–PEO polymer and subsequently covalently coated by 20 kDa branched poly(ethylene glycol), resulting in 135 ± 10 nm hydrodynamic diameter nanoclusters. The synthesized nanoclusters were found to have good stability in phosphate-buffered saline. The physicochemical and magnetic properties of the nanoclusters exhibit an efficient magnetic-to-thermal energy conversion with self-regulation of the hyperthermia temperature. Under irradiation to an alternating magnetic field (AMF) of 33 kA/m at a frequency of 300 kHz, the nanoclusters demonstrate a specific absorption rate (SAR) of 475 ± 17 W/g. The nanoclusters also exhibit a high transverse relaxivity of 68 (mM s)−1 at 1.5 T MRI. In preclinical studies, nanoclusters were intravenously injected to mice bearing 4T1 triple negative breast carcinoma lung metastases. Mice were irradiated by an AMF to demonstrate the antitumor efficacy, with 66% reduction in the number of metastases, which pave the route for the application of effective hyperthermia treatment for a metastatic cancer model.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoparticle-Based Drug Delivery · Characterization and Applications of Magnetic Nanoparticles · Ultrasound and Hyperthermia Applications

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

New-Phase Nanotechnology Ltd., Petah Tikvah 4934829, Israel

Oncology Department, Shamir Medical Center, Zerifin 70300, Israel

Internal Noninfectious Diseases Department, Trakia University, Stara Zagora 6000, Bulgaria

Consultant in Toxicologic Pathology, Sackler School of Medicine, Tel Aviv University, Tel Aviv 69978, Israel

Division of Medical Oncology, University of Ottawa, Ottawa, Ontario K1N 6N5, Canada

Laboratory of Precision Nanomedicine, Shmunis School for Biomedicine and Cancer Research, George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv 69978, Israel

References (54)

Show source-provided references
1. 10.3322/caac.2138710.3322/caac.21387 ↗
2. 10.1016/0306-9877(79)90063-X10.1016/0306-9877(79)90063-X ↗
3. 10.1016/j.ctrv.2010.05.00110.1016/j.ctrv.2010.05.001 ↗
4. 10.1016/j.nantod.2019.10079510.1016/j.nantod.2019.100795 ↗
5. 10.1002/adma.20070009110.1002/adma.200700091 ↗
6. 10.1080/0265673050015836010.1080/02656730500158360 ↗
7. 10.1007/s11060-006-9195-010.1007/s11060-006-9195-0 ↗
8. 10.1007/s11060-010-0389-010.1007/s11060-010-0389-0 ↗
9. 10.2147/IJN.S4377010.2147/IJN.S43770 ↗
10. 10.3109/02656736.2013.82299310.3109/02656736.2013.822993 ↗
11. 10.1038/srep0165210.1038/srep01652 ↗
12. 10.1186/s12938-017-0327-x10.1186/s12938-017-0327-x ↗
13. 10.1021/am504270c10.1021/am504270c ↗
14. 10.1016/j.jmmm.2006.10.115610.1016/j.jmmm.2006.10.1156 ↗
15. 10.1039/C7NR00023E10.1039/C7NR00023E ↗
16. 10.1016/j.jmmm.2016.11.04910.1016/j.jmmm.2016.11.049 ↗
17. Hof, R.; Khandadash, R.; Fremder, E. Phase-Change Nanoparticle. U.S. Patent 10172939B2, 2019.
18. 10.1007/BF0321909310.1007/BF03219093 ↗
19. 10.1021/nn101617n10.1021/nn101617n ↗
20. 10.5858/arpa.2018-0343-RA10.5858/arpa.2018-0343-RA ↗
21. 10.1038/nnano.2011.9510.1038/nnano.2011.95 ↗
22. 10.1021/acs.jpcc.6b0200610.1021/acs.jpcc.6b02006 ↗
23. 10.1021/acsnano.9b0197910.1021/acsnano.9b01979 ↗
24. 10.1021/acsnano.8b0654210.1021/acsnano.8b06542 ↗
25. 10.1021/nn100190v10.1021/nn100190v ↗
26. 10.1021/acsnano.7b0176210.1021/acsnano.7b01762 ↗
27. 10.1021/acs.chemmater.5b0251010.1021/acs.chemmater.5b02510 ↗
28. 10.1080/02656736.2019.162831310.1080/02656736.2019.1628313 ↗
29. 10.1016/j.solener.2015.02.03510.1016/j.solener.2015.02.035 ↗
30. 10.3390/pharmaceutics1112067110.3390/pharmaceutics11120671 ↗
31. 10.1006/jcis.1999.627310.1006/jcis.1999.6273 ↗
32. 10.1021/ja067457e10.1021/ja067457e ↗
33. 10.1021/jp310771p10.1021/jp310771p ↗
34. 10.1111/j.1349-7006.2003.tb01438.x10.1111/j.1349-7006.2003.tb01438.x ↗
35. 10.1002/adfm.20170443410.1002/adfm.201704434 ↗
36. 10.1016/j.jmmm.2016.04.09510.1016/j.jmmm.2016.04.095 ↗
37. 10.1039/C7NR02356A10.1039/C7NR02356A ↗
38. 10.1016/j.jconrel.2014.04.01710.1016/j.jconrel.2014.04.017 ↗
39. 10.1021/la00007a07010.1021/la00007a070 ↗
40. 10.1007/s11051-014-2796-110.1007/s11051-014-2796-1 ↗
41. 10.3390/polym1006058510.3390/polym10060585 ↗
42. 10.1021/acsnano.9b0197910.1021/acsnano.9b01979 ↗
43. 10.1038/srep2054310.1038/srep20543 ↗
44. 10.1063/1.233578310.1063/1.2335783 ↗
45. 10.1021/nl400188q10.1021/nl400188q ↗
46. 10.1021/nn201822b10.1021/nn201822b ↗
47. Clinical Magnetic Resonance Imaging; Edelman, R. R., Hesselink, J. R., Zlatkin, M. B., Eds. Saunders Publishing Co.: Philadelphia, PA, 1996; p 2196.
48. 10.2217/nnm.15.2210.2217/nnm.15.22 ↗
49. FDA’s Center for Drug Evaluation and Research (CDEER). Guidance for Industry Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers, July 2005; Corpus ID: 17535338.
50. 10.1080/02656736.2018.143086710.1080/02656736.2018.1430867 ↗
51. 10.1080/02656736.2016.119501810.1080/02656736.2016.1195018 ↗
52. 10.1021/nn500299p10.1021/nn500299p ↗
53. 10.1021/acsnano.8b0390010.1021/acsnano.8b03900 ↗
54. 10.1186/1476-4598-12-15210.1186/1476-4598-12-152 ↗